Cara Therapeutics reported $171.5M in Current Assets for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Current Assets Change
Acadia Pharmaceuticals ACAD:US $ 640.92M 4.81M
Acelrx Pharmaceuticals ACRX:US $ 51.75M 7.22M
Aerie Pharmaceuticals AERI:US $ 275.95M 13.07M
Arena Pharmaceuticals ARNA:US $ 790.92M 199.52M
Biodelivery Sciences International BDSI:US $ 188.26M 7.8M
Cara Therapeutics CARA:US $ 171.5M 7.03M
Chugai Pharma 4519:JP Y 913595M 56472M
Depomed DEPO:US $ 112.54M 6.8M
Endo International Ordinary Shares ENDP:US $ 2748.95M 179.62M
Halozyme Therapeutics HALO:US $ 1017.3M 17.55M
Horizon Pharma HZNP:US $ 2413.92M 238.54M
JAZZ PHA JAZZ:US $ 2628.23M 325.74M
Neurocrine Biosciences NBIX:US $ 1005.7M 104.4M
Pacira Pharmaceuticals PCRX:US $ 822.35M 29.77M
Pain Therapeutics PTIE:US $ 251.92M 27.64M
Redhill Biopharma RDHL:US $ 83.12M 15.38M
Revance Therapeutics RVNC:US $ 293.88M 60.72M
Supernus Pharmaceuticals SUPN:US $ 668.38M 29.13M
Teva Pharmaceutical Industries TEVA:US $ 12154M 668M
Vanda Pharmaceuticals VNDA:US $ 461.81M 15.16M